期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肝癌组织中Fas和FasL mRNA表达水平的变化及其意义 被引量：6

Alteration of Fas/FasL mRNA Expression in Hepato carcinoma and Its Significance
下载PDF
导出
摘要 目的　探讨肝癌、癌旁及正常肝组织中Fas和FasL mRNA表达水平的变化与肝癌发生、发展的关系及其意义。方法　应用半定量RT PCR的方法检测肝癌(40例)、癌旁(40例)及正常肝(25 例)组织中Fas及FasLmRNA表达的相对含量。结果　正常肝组织、癌旁及肝癌组织中Fas 和FasL mRNA 表达的相对含量分别为0.792±0.039和0.245±0.043、0.857±0.031和0.429±0.035以及0.473±0.047和0.185±0.041。肝癌组织中Fas mRNA表达的相对含量明显低于正常肝组织和癌旁组织(P<0.05); 肝癌组织中FasL mRNA表达的相对含量亦明显低于正常肝组织(P<0.05)和癌旁组织(P<0.01),但癌旁组织中FasL mRNA表达的相对含量高于正常肝组织中的表达(P<0.05)。结论　肝癌组织不仅通过低表达Fas来逃避机体的免疫监视作用,而且还通过癌旁组织FasL的高表达,使与之接触的淋巴细胞(表达Fas)凋亡,最终使肝癌细胞逃脱机体的免疫杀伤作用,得以增殖和转移。 Objective To measure the expressions of Fas/FasL mRNA in normal liver, adjacent non-cancerous liver parenchyma and hepatocarcinoma, and to explore the relationship between the expressions of Fas/FasL mRNA in those tissues and the hepatocellular carcinogenesis. Methods Semi-quantity reverse transcript-ploymerase chain reaction(QRT-PCR) were performed to measure the relative quantity of the Fas and FasL mRNA expressions in normal liver ( n =25), adjacent non-cancerous liver parenchyma( n =40) and hepatocarcinoma( n =40). Results The relative quantity of Fas and FasL mRNA expressed in normal liver, adjacent non-cancerous liver parenchyma and hepatocarcinoma were 0.792±0.039 vs 0.245±0.043,0.857±0.031 vs 0.429±0.035 and 0.473±0.047 vs 0.185±0.041, respectively. The relative quantity of Fas mRNA expression in hepatocarcinoma was lower than that of normal liver tissue and adjacent non-cancerous liver parenchyrna ( P <0.05). The relative quantity of FasL mRNA expression in hepatocarcinoma was also lower than that of normal liver tissue ( P <0.05) and adjacent non-cancerous liver parenchyma ( P <0.01), but its expression in adjacent non-cancerous liver parenchyma was higher than that of normal liver tissue ( P <0.05).Conclusion Hepatorcarcinoma may escape the immune surveillance of the host, not only by means of reducing Fas expression, but also through adjacent non-cancerous liver parenchyma’s increasing expression of FasL to induce apoptosis of contact lymphocyte which highly expresses Fas.
作者 李海民 窦科峰 李韧 周景师 帝振宇 张福琴
机构地区 第四军医大学西京医院肝胆外科
出处 《中国普外基础与临床杂志》 CAS 2005年第3期284-286,共3页 Chinese Journal of Bases and Clinics In General Surgery
关键词 肝癌 癌旁组织 正常肝组织 FAS FASL mRNA 恶性肿瘤 Hepatocarcinoma Adjacent non-cancerous liver parenchyma Normal liver tissue Fas FasL mRNA
分类号 R735.7 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Shima Y, Nakao K, Nakashima T, et al. Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells [J]. Hepatology, 1999; 30(5):1215.
  • 2Suzuki A, Hayashida M, Kawano H, et al. Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression [J]. Hepatology, 2000; 32(4 Pt 1):796.
  • 3Ito Y, Monden M, Takeda T, et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma [J]. Br J Cancer, 2000; 82(6):1211.
  • 4张俊峰,石学涛,衣龙海,李胜,孙宝友,吴泰璜.Fas/FasL在肝癌免疫逃避中作用的探讨[J].山东医药,2002,42(16):1-2. 被引量：3
  • 5Higaki K, Yano H, Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues [J]. Am J Pathol, 1996; 149(2):429.
  • 6You KR, Shin MN, Park RK, et al. Activation of caspase-8 during N-(4-hydroxyphenyl)retinamide-induced apoptosis in Fas-defective hepatoma cells [J]. Hepatology, 2001; 34(6):1119.
  • 7梁云,陆斌,王华菁,李晓冬,崔贞福,郭亚军,刘彦君.p53基因、Fas/FasL在提高肝癌细胞化疗药物敏感性中的作用[J].中华实验外科杂志,2002,19(4):342-344. 被引量：5
  • 8Srand S, Hofmann WJ, Hug H, et al. Lymphcyte apoptosis induce by CD95(APO-1/Fas) Ligand-expressing tumor immune escape [J]. Science, 1996; 274(4):1363.
  • 9Roskams T, Libbrecht L, Van Damme B, et al. Fas and Fas ligand: strong co-expression in human hepatocytes surrounding hepatocellular carcinoma; can cancer induce suicide in peritumoural cells? [J]. J Pathol, 2000; 191(2):150.
  • 10Nagao M, Nakajima Y, Hisanaga M, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? [J]. Hepatology, 1999; 30(2):413.

二级参考文献14

  • 1[1]Cascino I, Papoff G, Demaria R,et al. Fas/APO-1(CD95) receptor lacting the intracytoplasmic signaling domain protects tumor cell from Fas-mediated apoptosis[J]. J Immunol,1996,156(1):13-17.
  • 2[2]Ando K, Hiroishi K, Kaneko T, et al. Perforin, Fas/Fas ligand and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus specific human CTL[J]. J Immunol,1997, 158(11):5283-5291.
  • 3[3]Ungefroren H,Voss M,Jansen M, et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis[J].Cancer Res,1998,18(23):1741-1749.
  • 4[4]Hahne M,Rimoldi D,Schroter M, et al. Melamoma cell expression of Fas(APO-1/CD95) ligand:implications for tumor immune escape[J]. Science,1996, 274(5291):1363-1366.
  • 5[5]Tanaka M, Itai T, Adachi M, et al.Downregulation of Fas ligand by shedding[J].Nat Med,1998, 4(1):31-36.
  • 6[6]O′Connell J, O′Sullivan GC, Collins JK,et al. The Fas counterattack:Fas-mediated T cell killing by colon cancer cells expressing Fas ligand [J]. J Exp Med,1996,184(3): 1075-1082.
  • 7[1]Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody to a cell surface antigen codown regulated with the receptor of tumor necrosis factor. J Exp Med, 1989,169(5):1749～1756.
  • 8[2]Hahne M, Rimoldi D, Schroter P, et al. Melanoma cell expression of Fas ligand: implications for tumor immune escape. Science, 1996,274:1363～1366.
  • 9[3]Moller P,Koretz K,Leithauser F, et al.Express of APO-1(CD95),a member of the NGF/TNF receptor superfamily, in normal and neoplastic epithelium. Int J Cancer.1994,57(2):371～374.
  • 10[4]Pan G, Vickers S M, Pickens A, et al.Tumorigenesis in human cholangiocarcinoma cells.Am J Pathol, 1999,15(1):193～203.

共引文献11

同被引文献71

引证文献6

二级引证文献29

中国普外基础与临床杂志
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部